Navigation Links
Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
Date:11/12/2007

to our Phase IIb clinical trial for TRU-015, increased personnel- related expenses due to increased headcount, and increased outside manufacturing costs related to our TRU-016 product candidate. These increases were partially offset by lower outside manufacturing costs for TRU-015 due to the successful transfer of manufacturing activities to Wyeth during 2007 and lower noncash stock-based compensation charges.

Net loss for the third quarter and nine months ended Sept. 30, 2007, was $5.9 million, or $0.33 per diluted common share, and $18.4 million, or $1.04 per diluted common share, respectively, compared with net income of $5.4 million, or $0.40 per diluted common share, and $871,000, or $0.06 per diluted common share respectively in 2006.

Trubion had $86.6 million in cash, cash equivalents and investments as of Sept. 30, 2007, compared with $90.3 million as of June 30, 2007.

"We are pleased with our progress in the third quarter," said Peter Thompson, M.D., FACP, Trubion's president, chief executive officer and chairman. "We continued to advance the development of multiple product candidates and reported positive preliminary results of our Phase IIb trial evaluating TRU-015 for the treatment of Rheumatoid Arthritis. In the fourth quarter we expect to begin TRU-015 Phase I clinical trials for both Systemic Lupus Erythematosus and non-Hodgkin's lymphoma, and have recently filed an investigational new drug application for our proprietary candidate, TRU-016 for B-cell malignancies."

2007 Financial Guidance

As a result of lower anticipated reimbursement revenue and lower expenses due primarily to the successful transfer of manufacturing activities for TRU-015 from Trubion to Wyeth, the company expects 2007 results to fall within the low end of, or slightly below, its previously provided ranges. The guidance ranges previously provided by the company include:

-- Revenue - $20 million to $25 million. Revenue is generated from fees,


'/>"/>
SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014 Amgen (NASDAQ: ... Directors today declared a $0.61 per share dividend for ... paid on Sept. 5, 2014, to all stockholders of ... 14, 2014.  About Amgen Amgen is ... suffering from serious illnesses by discovering, developing, manufacturing and ...
(Date:7/25/2014)... , July 25, 2014 Research ... "Global Metabolomics Market 2014-2018" report to ... Metabolomics or Metabonomics is the ... has become a new experimental technique that is ... environmental sciences. Metabolites are small molecules that are ...
(Date:7/25/2014)... Pittsburgh, PA (PRWEB) July 25, 2014 ... annual Call for Topics for Conferee Networking. These two-hour ... similar interests to meet and resolve problems, discuss new ... , The deadline to submit a topic for consideration ... at pittcon.org . The Conferee Networking committee will ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion Corporation, ... for global corporations operating in highly regulated industries, ... first annual Global User Group Conference, Xybion International ... Philadelphia, Pennsylvania at the Sheraton ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s conference ...
Breaking Biology Technology:Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Pittcon 2015 Announces Call for Topics for Conferee Networking Sessions 2Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... /PRNewswire-Asia-FirstCall/ -- ... ... var shortURL = ""; ... we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; break; ...
... Sept. 7 The Plasma Protein Therapeutics Association (PPTA) ... (CMS) finalize its Proposed Rule regarding reimbursement to better ... outpatient setting. Specifically, for CY 2011, ... payable non-pass-through drugs and biologicals, which include most plasma ...
... Md., Sept. 3 The Maryland Stem Cell Research ... Cell Research Symposium in partnership with the National Institutes ... and Technology (NIST) on Wednesday, Sept. 22, 2010. The ... Life Science Research," will be held at the NIST ...
Cached Biology Technology:Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 2Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 3Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 4Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 5Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 6Yongye International to Present at Rodman & Renshaw Annual Global Investment Conference 7PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 2PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 3Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium 2Maryland Stem Cell Research Commission to Host Third Annual Maryland Stem Cell Research Symposium 3
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... numbers have decreased by 45% on average over a ... reports a study on the impact of humans on ... enormous benefits invertebrates such as insects, spiders, crustaceans, slugs ... and pest control for crops, decomposition for nutrient cycling, ... in Science and led by UCL, Stanford ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4NYSCF scientists 1 step closer to cell therapy for multiple sclerosis patients 2Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3
... rainfall are affecting the survival of elephants working in ... of death in calves aged up to five, new ... With climate change models predicting higher temperatures and ... already endangered Asian elephants. The researchers matched monthly ...
... TN Since the mid-nineteenth century, maps have helped ... yellow fever. Yet today,s global mapping of infectious diseases ... the control of potential outbreaks, according to a new ... known to humans., Of the 355 infectious diseases assessed ...
... mental health leads to unhealthy behaviors in low-income adults ... new study by Dr. Jennifer Walsh and colleagues from ... Miriam Hospital in the US. In this study, stress ... binge drinking, illegal drug use, unprotected sex and unhealthy ...
Cached Biology News:Low rainfall and extreme temperatures double risk of baby elephant deaths 2Avoiding a cartography catastrophe 2Poor mental health leads to unhealthy behaviors among low-income adults 2
RAB32, member RAS oncogene family, mRNA (cDNA clone MGC:13500 IMAGE:4280407), complete cds...
EDTA, 0.5 M solution, 100 ml. Ethylene diaminetetraacetic acid.Sterile, nuclease-free. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Human VEGF-D Biotinylated MAb (Clone 78923)...
One-step, microplate or cuvet, colorimetric, linear detection range 0.2 mg/dL to 20 mg/dL. Procedure: 20 min....
Biology Products: